Galapagos NV (NASDAQ:GLPG) had its target price lifted by stock analysts at Nomura from $108.00 to $124.00 in a report issued on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock. Nomura’s target price suggests a potential upside of 52.97% from the stock’s current price.

Other analysts also recently issued reports about the company. Cowen and Company reiterated a “buy” rating on shares of Galapagos NV in a research report on Thursday. Morgan Stanley restated an “overweight” rating and issued a $92.00 price objective on shares of Galapagos NV in a report on Thursday. Stifel Nicolaus upgraded Galapagos NV from a “hold” rating to a “buy” rating and lifted their price objective for the company from $83.00 to $101.00 in a report on Friday. BTIG Research restated a “buy” rating and issued a $98.00 price objective on shares of Galapagos NV in a report on Tuesday, June 20th. Finally, Janney Montgomery Scott upgraded Galapagos NV from a “sell” rating to a “neutral” rating in a report on Friday, July 7th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $96.14.

Shares of Galapagos NV (NASDAQ:GLPG) traded up 3.63% on Friday, reaching $84.00. 261,325 shares of the company’s stock were exchanged. Galapagos NV has a one year low of $52.50 and a one year high of $94.88. The stock’s market cap is $4.27 billion. The company’s 50 day moving average is $77.64 and its 200-day moving average is $79.02.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/galapagos-nv-glpg-pt-raised-to-124-00-at-nomura.html.

Large investors have recently modified their holdings of the company. UBS Group AG raised its stake in shares of Galapagos NV by 237.0% in the first quarter. UBS Group AG now owns 3,522 shares of the biotechnology company’s stock worth $303,000 after buying an additional 2,477 shares during the last quarter. Cim Investment Mangement Inc. acquired a new stake in shares of Galapagos NV during the first quarter worth $203,000. Marshall Wace North America L.P. acquired a new stake in shares of Galapagos NV during the first quarter worth $989,000. MARSHALL WACE ASIA Ltd acquired a new stake in shares of Galapagos NV during the first quarter worth $989,000. Finally, Bogle Investment Management L P DE acquired a new stake in shares of Galapagos NV during the first quarter worth $368,000. Institutional investors and hedge funds own 19.99% of the company’s stock.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.